139 related articles for article (PubMed ID: 16650445)
1. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers.
Lamolle G; Marin M; Alvarez-Valin F
Mutat Res; 2006 Aug; 600(1-2):102-12. PubMed ID: 16650445
[TBL] [Abstract][Full Text] [Related]
2. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
[TBL] [Abstract][Full Text] [Related]
3. Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs).
Gorlov IP; Gorlova OY; Frazier ML; Amos CI
Mutat Res; 2004 Oct; 554(1-2):175-83. PubMed ID: 15450416
[TBL] [Abstract][Full Text] [Related]
4. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.
Walker DR; Bond JP; Tarone RE; Harris CC; Makalowski W; Boguski MS; Greenblatt MS
Oncogene; 1999 Jan; 18(1):211-8. PubMed ID: 9926936
[TBL] [Abstract][Full Text] [Related]
5. Li-Fraumeni and Li-Fraumeni-like syndrome mutations in p53 are associated with exonic methylation and splicing regulatory elements.
Kouidou S; Malousi A; Maglaveras N
Mol Carcinog; 2009 Oct; 48(10):895-902. PubMed ID: 19367569
[TBL] [Abstract][Full Text] [Related]
6. Selective pressures at a codon-level predict deleterious mutations in human disease genes.
Arbiza L; Duchi S; Montaner D; Burguet J; Pantoja-Uceda D; Pineda-Lucena A; Dopazo J; Dopazo H
J Mol Biol; 2006 May; 358(5):1390-404. PubMed ID: 16584746
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency.
Hill KA; Wang J; Farwell KD; Scaringe WA; Sommer SS
Mutat Res; 2004 Oct; 554(1-2):223-40. PubMed ID: 15450421
[TBL] [Abstract][Full Text] [Related]
8. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations.
Shahedian B; Shi Y; Zou M; Farid NR
Mol Genet Metab; 2001 Feb; 72(2):155-63. PubMed ID: 11161841
[TBL] [Abstract][Full Text] [Related]
9. Methylation and repeats in silent and nonsense mutations of p53.
Kouidou S; Malousi A; Maglaveras N
Mutat Res; 2006 Jul; 599(1-2):167-77. PubMed ID: 16620878
[TBL] [Abstract][Full Text] [Related]
10. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
11. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
12. The UMD-p53 database: new mutations and analysis tools.
Béroud C; Soussi T
Hum Mutat; 2003 Mar; 21(3):176-81. PubMed ID: 12619103
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection.
Soussi T; Asselain B; Hamroun D; Kato S; Ishioka C; Claustres M; Béroud C
Clin Cancer Res; 2006 Jan; 12(1):62-9. PubMed ID: 16397025
[TBL] [Abstract][Full Text] [Related]
14. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
15. Splice mutations in the p53 gene: case report and review of the literature.
Holmila R; Fouquet C; Cadranel J; Zalcman G; Soussi T
Hum Mutat; 2003 Jan; 21(1):101-2. PubMed ID: 12497643
[TBL] [Abstract][Full Text] [Related]
16. Determination of sensitive positions to mutations in human p53 protein.
Wu G; Yan S
Biochem Biophys Res Commun; 2004 Aug; 321(2):313-9. PubMed ID: 15358177
[TBL] [Abstract][Full Text] [Related]
17. Structural assessment of single amino acid mutations: application to TP53 function.
Yip YL; Zoete V; Scheib H; Michielin O
Hum Mutat; 2006 Sep; 27(9):926-37. PubMed ID: 16917930
[TBL] [Abstract][Full Text] [Related]
18. Use of mutation spectra analysis software.
Rogozin I; Kondrashov F; Glazko G
Hum Mutat; 2001 Feb; 17(2):83-102. PubMed ID: 11180592
[TBL] [Abstract][Full Text] [Related]
19. Screen p53 mutations in hepatocellular carcinoma by FASAY: a novel splicing mutation.
Wu XM; Fu JG; Ge WZ; Zhu JY; Wang JY; Zhang W; Qian W; Huo KK
J Zhejiang Univ Sci B; 2007 Feb; 8(2):81-7. PubMed ID: 17266182
[TBL] [Abstract][Full Text] [Related]
20. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.
Kamihira S; Terada C; Sasaki D; Yanagihara K; Tsukasaki K; Hasegawa H; Yamada Y
Eur J Haematol; 2009 Apr; 82(4):301-7. PubMed ID: 19220422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
